DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Belinostat
Belinostat
Vorinostat—An Overview Aditya Kumar Bubna
Peripheral T-Cell Lymphomas
Belinostat (Beleodaq®)
Histone Deacetylase Inhibitors
151109EN ASH Abstract
A Phase I/II Trial of Belinostat in Combination with Cisplatin, Doxorubicin, and Cyclophosphamide in Thymic Epithelial Tumors: a Clinical and Translational Study
Medical Drug Benefit Clinical Criteria Updates
Beleodaq® (Belinostat)
Phase I Pharmacokinetic Study of Belinostat for Solid Tumors and Lymphomas in Patients with Varying Degrees of Hepatic Dysfunction
Belinostat and Combo Therapies in T Cell Lymphoma
206256Orig1s000
Histone Deacetylase Inhibitors Dose-Dependently Switch Neutrophil Death from Netosis to Apoptosis
Standard Oncology Criteria C16154-A
Combination Therapy of Bortezomib with Novel Targeted Agents: an Emerging Treatment Strategy
BELEODAQ (Belinostat) for Injection, for Intravenous Administration • Hepatotoxicity: Beleodaq May Cause Hepatic Toxicity and Liver Function Test Initial U.S
Istodax CE Model Poster for AMCP
Spectrum Pharmaceuticals Appoints Steven M. Fruchtman, MD, an Industry Veteran, As Vice President of Clinical Development
Spectrum Pharmaceuticals and Onxeo Announce Complete Response In
Top View
Histone Deacetylase Inhibitors in the Treatment of Multiple Myeloma
Romidepsin and Belinostat Synergize the Antineoplastic Effect of Bortezomib in Mantle Cell Lymphoma
Pharmacogenomic Associations Tables
Spectrum Pharmaceuticals Provides Update on Belinostat Registrational Trial for the Treatment of Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)
Bc Cancer Chemotherapy Preparation and Stability
Profile of Belinostat for the Treatment of Relapsed Or Refractory Peripheral T-Cell Lymphoma
Belinostat: Past and Future
FDA Approval: Belinostat for the Treatment of Patients with Relapsed Or Refractory
Peripheral T-Cell Lymphoma Facts No
BELEODAQ (Belinostat) RATIONALE for INCLUSION in PA PROGRAM
Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma
A Phase I/II Clinical Trial of Belinostat (PXD101) in Combination with Doxorubicin in Patients with Soft Tissue Sarcomas
Clinically Relevant Concentrations of Anticancer Drugs: a Guide for Nonclinical Studies Dane R
Personalized in Vitro and in Vivo Cancer Models to Guide Precision Medicine
Synergistic Antitumor Effects of the Combined Treatment with an HDAC6 Inhibitor and a COX-2 Inhibitor Through Activation of PTEN
Cross Discipline Team Leader Review
Investigator Brochure
HDACI): in Vitro and in Vivo Studies in Thyroid Cancer
Leukemia Insights Spring 2011
HDAC Screening Identifies the HDAC Class I Inhibitor Romidepsin As A
Computationally Predicting Clinical Drug Combination Efficacy With
HDAC Inhibitors: Dissecting Mechanisms of Action to Counter Tumor Heterogeneity
Belinostat (Interim Monograph)
Adult Antiemetic Management of Chemotherapy-Induced Nausea
Combination Thermochemotherapy for the Treatment of Non-Muscle Invasive Bladder Cancer Ramy Said Goueli Yale School of Medicine,
[email protected]
Randomized Phase II Trial of a First-In-Human Cancer Cell Lysate Vaccine in Patients with Thoracic Malignancies
Beleodaq™(Belinostat)
Nanoparticles for Urothelium Penetration and Delivery of the Histone Deacetylase Inhibitor Belinostat for Treatment of Bladder Cancer Darryl T
How LLS Is Changing the Landscape of Blood Cancer
Beleodaq® (Belinostat)
Oncology Proposal
Supplementary Table S1. Preclinical Studies of Combinations Of
Prolonging the Half-Life of Histone Deacetylase Inhibitor Belinostat Via 50 Nm Scale Liposomal Subcutaneous Delivery System for Peripheral T-Cell Lymphoma
Belinostat (Beleodaq) with CHOP for Treatment of Patients with Peripheral T‐Cell Lymphoma, 1St Line NIHRIO (HSRIC) ID: 12674 NICE ID: 9532
USP Medicare Model Guidelines V7.0 (With Example Part D Drugs)
Cancer Therapy: Clinical Research
Belinostat in Combination with Standard Cyclophosphamide
Efficacy of HDAC Inhibitors Belinostat and Panobinostat Against Cisplatin-Sensitive and Cisplatin-Resistant Testicular Germ Cell Tumors
Risk Assessment and Risk Mitigation Review(S)
206256Orig1s000
Emetic Risk of Single Intravenous Antineoplastic Agents in Adults
Panobinostat Acts Synergistically with Ibrutinib in Diffuse Large B Cell Lymphoma Cells with Myd88 L265 Mutations
Standard Oncology Criteria Policy Number: Pending
[2016]. NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2016
Cancer Drug Costs for a Month of Treatment at Initial Food and Drug Administration Approval
Characteristics of Non-Randomized Studies Using Comparisons with External Controls Submitted for Regulatory Approval in the Us and Europe: a Systematic Review
Year of FDA Monthly Cost Approval
FDA Approval: Belinostat for the Treatment of Patients with Relapsed Or Refractory Peripheral T-Cell Lymphoma Hyon-Zu Lee1, Virginia E
Do Not Tube List
206256Orig1s000
Belinostat) – Medicaid
Investigation of Belinostat-Induced Genomic Instability by Molecular
Marine Power on Cancer: Drugs, Lead Compounds, and Mechanisms
Efficacy of HDAC Inhibitors Belinostat and Panobinostat Against
Hazardous Drug List
Combining Oncolytic Viruses and Small Molecule Therapeutics: Mutual Benefits
Managing Pharmacotherapy in People Living with HIV And